|
The 24 month is significant because for all bc patients, the peak rate of recurrence maximizes around 18 to 24 months after first diagnosis. This has a theoretical basis from the cell division rate from a few cells to a palpable mass. The time coincides with the observed peak of 18 to 24 months. Now for HER2 patients, the peak probably is shorter. My guess is around 12 to 18 months. Regardless, after 24 months, the probability of recurrence goes down for all bc patients. That is the reason for my notation of significance.
__________________
Ann
Stage 1 dx Sept 05
ER/PR positive HER2 +++ Grade 3
Invasive carcinoma 1 cm, no node involvement
Mastec Sept 05
Annual scans all negative, Oct 06
Postmenopause. Arimidex only since Sept 06, bone or muscle ache after 3 month
Off Arimidex, change to Femara 1/12-07, ache stopped
Sept 07 all tests negative, pass 2 year mark
Feb 08 continue doing well.
Sep 09 four year NED still on Femara.
|
Hybrid Mode
